Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Shuhua Han"'
Autor:
Yuankai Shi, Kaijian Lei, Yuming Jia, Bingqiang Ni, Zhiyong He, Minghong Bi, Xicheng Wang, Jianhua Shi, Ming Zhou, Qian Sun, Guolei Wang, Dongji Chen, Yongqian Shu, Lianke Liu, Zhongliang Guo, Yong Liu, Junquan Yang, Ke Wang, Ke Xiao, Lin Wu, Tienan Yi, Debin Sun, Mafei Kang, Tianjiang Ma, Yimin Mao, Jinsheng Shi, Tiegang Tang, Yan Wang, Puyuan Xing, Dongqing Lv, Wangjun Liao, Zhiguo Luo, Bin Wang, Xiaohong Wu, Xiaoli Zhu, Shuhua Han, Qisen Guo, Rongyu Liu, Zhiwei Lu, Jianyong Zhang, Jian Fang, Changlu Hu, Yinghua Ji, Guolong Liu, Hong Lu, Dedong Wu, Junhong Zhang, Shuyang Zhu, Zheng Liu, Wensheng Qiu, Feng Ye, Yan Yu, Yanqiu Zhao, Qinhong Zheng, Jun Chen, Zhanyu Pan, Yiping Zhang, Wenjuan Lian, Bo Jiang, Bo Qiu, Guojun Zhang, Hua Zhang, Yanju Chen, Yuan Chen, Hongbing Duan, Manxiang Li, Shengming Liu, Lijun Ma, Hongming Pan, Xia Yuan, Xueli Yuan, Yulong Zheng, Emei Gao, Li Zhao, Shumin Wang, Can Wu
Publikováno v:
Cancer Communications, Vol 41, Iss 9, Pp 889-903 (2021)
Abstract Background Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized con
Externí odkaz:
https://doaj.org/article/1b6a8c7c86df46eb82dde4f6b77d922e
Autor:
Zhongliang Guo, Jian Fang, Junhong Zhang, Puyuan Xing, Xiaoli Zhu, Changlu Hu, Yuming Jia, Ming Zhou, Zhiwei Lu, Bin Wang, Ke Wang, Yiping Zhang, Lin Wu, Zhanyu Pan, Yanju Chen, Junquan Yang, Shuhua Han, Yongqian Shu, Lianke Liu, Bingqiang Ni, Yong Liu, Hongming Pan, Rongyu Liu, Shengming Liu, Qian Sun, Feng Ye, Qinhong Zheng, Guojun Zhang, Tiegang Tang, Tianjiang Ma, Jianyong Zhang, Bo Jiang, Mafei Kang, Zhiguo Luo, Wenjuan Lian, Can Wu, Lijun Ma, Zhiyong He, Wensheng Qiu, Dongqing Lv, Zheng Liu, Qisen Guo, Dedong Wu, Ke Xiao, Xia Yuan, Jun Chen, Yan Yu, Yuankai Shi, Guolei Wang, Dongji Chen, Shuyang Zhu, Jianhua Shi, Guolong Liu, Hua Zhang, Hongbing Duan, Bo Qiu, Wangjun Liao, Shumin Wang, Jinsheng Shi, Tienan Yi, Hong Lu, Xueli Yuan, Emei Gao, Yimin Mao, Xicheng Wang, Li Zhao, Xiaohong Wu, Yanqiu Zhao, Yan Wang, Kaijian Lei, Yinghua Ji, Yulong Zheng, Minghong Bi, Manxiang Li, Debin Sun, Yuan Chen
Publikováno v:
Cancer Communications, Vol 41, Iss 9, Pp 889-903 (2021)
Cancer Communications
Cancer Communications
Background Previous studies have demonstrated the preclinical pharmacological and toxicological consistency, and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab (Avastin). This randomized controlled t